GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM on the occasion of the ASCO (American Society of Clinical Oncology) annual convention, held from 1 July to 2 July.er to June 5 in Chicago. The miR31now test is the first positive theranostic test indicated for mRCC patients. It is predictive of the efficacy of first-line treatment with anti-EGFR compared with first-line treatment with anti-VEGF, as well as second- or third-line treatment compared with chemotherapy alone for patients with wild-type mRCC.
miR-31now quantifies the level of 31-3p microRNA expression in a formalin-fixed, paraffin-embedded (FFPE) tumor sample, using standard quantitative reverse transcriptase (RT-qPCR) technology. It will be marketed in the USA and Canada as a complement to other mRCC tests, including those for KRAS and RAS mutations.
GoPath Laboratories announced in January 2018 the signing of a license agreement with IntegraGen, carrying the miR-31-3P biomarker expression measurement assay. IntegraGen will continue to sell the CE-IVD-marked miRpredX kit in parallel in Europe and other regions.
Leave a Reply